ABIO Stock Summary and Trading Ideas (Arca Biopharma | NASDAQ:ABIO)

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Arca Biopharma trades on the NASDAQ stock market under the symbol ABIO.

As of September 13, 2024, ABIO stock price was flat at $2.40 with million shares trading.

ABIO has a beta of 6.41, meaning it tends to be more sensitive to market movements. ABIO has a correlation of 0.10 to the broad based SPY ETF.

ABIO has a market cap of $2.90 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ABIO stock traded as high as $53.88 and as low as $2.40.

The top ETF exchange traded funds that ABIO belongs to (by Net Assets): VTI, VXF.

ABIO has outperformed the market in the last year with a return of +70.4%, while the SPY ETF gained +27.4%. However, in the most recent history, ABIO shares have underperformed the stock market with its stock returning +3.2% in the last 3 month period and -91.7% for the last 2 week period, while SPY has returned +3.9% and -0.3%, respectively.

ABIO support price is $2.28 and resistance is $2.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABIO stock will trade within this expected range on the day.